Tests meal replacements for blood sugar control in type 2 diabetes
Tests meal replacement therapy in adults with uncontrolled type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of Meal Replacement Therapy on Glucose Control and Metabolic Parameters in Patients With Uncontrolled Diabetes
Key facts
- Where
- Kubang Kerian, MalaysiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT06862180, who can take part
Where in Malaysia
- Hospital Universiti Sains MalaysiaKubang Kerian, MalaysiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universiti Sains Malaysia
- Trial code
- NCT06862180
- Record updated
- 6 March 2025
- Original description
To evaluate the effect of meal replacement therapy on glucose control and other metabolic parameters in patients with uncontrolled type 2 diabetes.Read full original descriptionShow less
The Effect of Meal Replacement Therapy on Glucose Control and Other Metabolic Parameters in Patients With Uncontrolled Type 2 Diabetes on Oral Hypoglycemic Agents: A Randomized Controlled Trial
To evaluate the effect of meal replacement therapy on glucose control and other metabolic parameters in patients with uncontrolled type 2 diabetes.
Methodology:
This is an open-label, prospective, randomized control trial study. Study duration. August 2023 - March 2026. Study location. This study will be conducted at the Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia.
Source Reference :
People with type 2 diabetes mellitus attending the Hospital Universiti Sains Malaysia.
Study source population :
People with type 2 diabetes mellitus attended Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia during the study period.
Inclusion: Patients between ≥ 30 to ≤ 65 years old; Diagnosed as having type 2 diabetes mellitus base on CPG Malaysia Clinical Practice Guidelines (CPG) for Type 2 Diabetes Mellitus (T2DM) 6th edition 2020; On oral hypoglycaemic agent(s); HbA1c 7- 10 % (result 3 months from the date of recruitment); Agree not to take other beverages, herbal or nutritional supplements for the duration of the study.
Exclusion: Severe diabetic complication(s) including end-stage renal disease and proliferative retinopathy; Patients with advanced liver disease, such as non-alcoholic steatohepatitis (NASH) with significant fibrosis (e.g., liver stiffness measurement > 9.5 kPa by FibroScan) or cirrhosis; Patients with chronic kidney disease with eGFR ≤ 25 ml/min; Patients with significantly elevated liver enzymes (e.g., ALT or AST ≥ 3 times the upper limit of normal), which may indicate more severe liver damage; Pregnancy or plan to get pregnant during the study period; Newly diagnosed diabetic less than 3 months from the date of recruitment; Currently involve in any weight loss program; Currently consuming any meal replacement product.